{
    "2019-05-08": [
        [
            {
                "time": "2019-05-08",
                "original_text": "Novartis buys Takeda's dry eye drug for $3.4 bln",
                "features": {
                    "keywords": [
                        "Novartis",
                        "buys",
                        "Takeda",
                        "dry eye",
                        "drug",
                        "$3.4 bln"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-05-08",
                "original_text": "Novartis buys dry-eye drug Xiidra rights from Takeda for $3.4 billion",
                "features": {
                    "keywords": [
                        "Novartis",
                        "buys",
                        "dry-eye",
                        "drug",
                        "Xiidra",
                        "rights",
                        "Takeda",
                        "$3.4 billion"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-05-08",
                "original_text": "Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates",
                "features": {
                    "keywords": [
                        "Aduro",
                        "Q1",
                        "Earnings",
                        "Revenues",
                        "Fall",
                        "Shy",
                        "Estimates"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-05-08",
                "original_text": "Novartis confident of Zolgensma supply, calls $2 million price 'speculation'",
                "features": {
                    "keywords": [
                        "Novartis",
                        "confident",
                        "Zolgensma",
                        "supply",
                        "$2 million",
                        "price",
                        "speculation"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-05-08",
                "original_text": "Validea Peter Lynch Strategy Daily Upgrade Report - 5/8/2019",
                "features": {
                    "keywords": [
                        "Validea",
                        "Peter Lynch",
                        "Strategy",
                        "Daily",
                        "Upgrade",
                        "Report"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}